Table 1.
Study | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
Yoshitake et al. [47] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ||
Borenstein et al. [44] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | |
Gustafson et al. [43] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ |
Nourhashemi et al. [29] | ★ | ★ | ★ | ★ | ★ | |||||
Buchman et al. [50] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | |
Hayden et al. [41] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ||
Lunchsinger et al. [33] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | |
Atti et al. [30] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | |
Dahl et al. [31] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ |
Hughes et al. [32] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ |
Fitzpatrick et al. [35] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | |
Scarmeas et al. [46] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ |
Power et al. [34] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | |
Lucca et al. [28] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | |||
Tolppanen et al. [52] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | |
Neergaard et al. [42] | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ |
(1) Cohort truly representative; (2) Controls from the same cohort; (3) Clear measurement of obesity at baseline; (4) Adequacy of Follow-up duration (≥24 months); (5) Reliable methods of dementia and AD diagnosis (i.e., Quality of outcome); (6) Data analysis controlled for smoking and medical co-morbidities; (7) Data analysis controlled for any other three confounders (Age, social class/education, alcohol, ApoE4 carrier status, medical therapies and ethnicity etc.); (8) Findings interpreted well; (9) Weakness mentioned and explained clearly; (10) Paper written well.